NCT02615106

Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma

Phase 2 Study of Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of Radiotherapy plus Endostar(Recombinant Human Endostatin) in patients with Pediatric Neuroblastoma.

Detailed description

Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. So investigators design Radiotherapy plus Endostar to treat Pediatric Neuroblastoma to research the RR and safety. Investigators believe this treatment regimen may be a new approach to the pediatric neuroblastoma patients.

Conditions

• Neuroblastoma

Interventions

Type	Name	Description
DRUG	Endostar	7.5 mg/m2/day, day 1-14
RADIATION	21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor	21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor

Timeline

• Start date: 2015-11-01
• Primary completion: 2017-11-01
• Completion: 2018-11-01
• First posted: 2015-11-25
• Last updated: 2016-06-14

Locations

1 site across 1 country: China